NO325601B1 - Anvendelse av et preparat for fremstilling av et medikament for a behandle organ-vevsskade. - Google Patents

Anvendelse av et preparat for fremstilling av et medikament for a behandle organ-vevsskade. Download PDF

Info

Publication number: NO325601B1
Authority: NO; Norway
Prior art keywords: glp; stated; peptide; receptor; administration
Prior art date: 1999-04-30

Application number

NO20015294A

Other languages

English (en)

Norwegian (no)

Other versions

NO20015294L (no

NO20015294D0 (no

Inventor

Thomas R Coolidge

Mario R W Ehlers

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-30

Filing date

2001-10-29

Publication date

2008-06-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO325601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-10-29 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2001-10-29 Publication of NO20015294D0 publication Critical patent/NO20015294D0/no

2001-12-28 Publication of NO20015294L publication Critical patent/NO20015294L/no

2008-06-23 Publication of NO325601B1 publication Critical patent/NO325601B1/no

Links

210000000056 organ Anatomy 0.000 title claims 3
239000003814 drug Substances 0.000 title claims 2
238000004519 manufacturing process Methods 0.000 title claims 2
239000000203 mixture Substances 0.000 title claims 2
230000000451 tissue damage Effects 0.000 title claims 2
231100000827 tissue damage Toxicity 0.000 title claims 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 11
101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 9
102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 9
108090000765 processed proteins & peptides Proteins 0.000 claims 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
230000000302 ischemic effect Effects 0.000 claims 3
238000000034 method Methods 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 2
239000008103 glucose Substances 0.000 claims 2
238000002347 injection Methods 0.000 claims 2
239000007924 injection Substances 0.000 claims 2
230000007246 mechanism Effects 0.000 claims 2
230000010410 reperfusion Effects 0.000 claims 2
239000012266 salt solution Substances 0.000 claims 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
239000004475 Arginine Substances 0.000 claims 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
108010011459 Exenatide Proteins 0.000 claims 1
229940123457 Free radical scavenger Drugs 0.000 claims 1
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 1
206010022657 Intestinal infarction Diseases 0.000 claims 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
229930195725 Mannitol Natural products 0.000 claims 1
229910019142 PO4 Inorganic materials 0.000 claims 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
230000017531 blood circulation Effects 0.000 claims 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
238000011260 co-administration Methods 0.000 claims 1
230000006378 damage Effects 0.000 claims 1
230000003111 delayed effect Effects 0.000 claims 1
239000008121 dextrose Substances 0.000 claims 1
229960001519 exenatide Drugs 0.000 claims 1
108010015174 exendin 3 Proteins 0.000 claims 1
LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 claims 1
108700005418 glucagon-like peptide-1 (9-36)-amide Proteins 0.000 claims 1
239000007943 implant Substances 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
208000028867 ischemia Diseases 0.000 claims 1
239000008101 lactose Substances 0.000 claims 1
238000011542 limb amputation Methods 0.000 claims 1
210000004072 lung Anatomy 0.000 claims 1
239000000594 mannitol Substances 0.000 claims 1
235000010355 mannitol Nutrition 0.000 claims 1
239000012528 membrane Substances 0.000 claims 1
230000002503 metabolic effect Effects 0.000 claims 1
208000010125 myocardial infarction Diseases 0.000 claims 1
210000004165 myocardium Anatomy 0.000 claims 1
239000010452 phosphate Substances 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
229910052700 potassium Inorganic materials 0.000 claims 1
239000011591 potassium Substances 0.000 claims 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
239000002516 radical scavenger Substances 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 claims 1
238000001356 surgical procedure Methods 0.000 claims 1
230000000472 traumatic effect Effects 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicinal Preparation (AREA)

NO20015294A 1999-04-30 2001-10-29 Anvendelse av et preparat for fremstilling av et medikament for a behandle organ-vevsskade. NO325601B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/302,596 US6284725B1 (en)	1998-10-08	1999-04-30	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
PCT/US2000/011251 WO2000066138A2 (fr)	1999-04-30	2000-04-27	Intervention metabolique au moyen d'un peptide 1 du type gucagon (glp-1) permettant d'ameliorer une lesion d'un tissu provoquee par une ischemie et une reperfusion

Publications (3)

Publication Number	Publication Date
NO20015294D0 NO20015294D0 (no)	2001-10-29
NO20015294L NO20015294L (no)	2001-12-28
NO325601B1 true NO325601B1 (no)	2008-06-23

Family

ID=23168436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015294A NO325601B1 (no)	1999-04-30	2001-10-29	Anvendelse av et preparat for fremstilling av et medikament for a behandle organ-vevsskade.

Country Status (16)

Country	Link
US (3)	US6284725B1 (fr)
EP (2)	EP1173197B2 (fr)
JP (1)	JP2002543142A (fr)
CN (1)	CN1349409A (fr)
AT (1)	ATE283701T1 (fr)
AU (2)	AU777019B2 (fr)
CA (1)	CA2372947C (fr)
DE (1)	DE60016393T3 (fr)
ES (1)	ES2233366T5 (fr)
HK (1)	HK1046640A1 (fr)
IL (2)	IL145830A0 (fr)
MX (1)	MXPA01010859A (fr)
NO (1)	NO325601B1 (fr)
NZ (1)	NZ514610A (fr)
PT (1)	PT1173197E (fr)
WO (1)	WO2000066138A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) *	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en) *	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6924264B1 (en) *	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
BR0010750A (pt) *	1999-05-17	2002-02-26	Conjuchem Inc	Peptìdeos insulinotrópicos de longa duração
US20060160740A1 (en) *	1999-10-21	2006-07-20	Suad Efendic	Use of GLP-1 or analogs in treatment of stroke
US6485938B1 (en) *	1999-11-16	2002-11-26	Zymogenetics, Inc.	Nucleic acid molecules that encodes human Zven1
EP2213743A1 (fr)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
CN103356996A (zh) *	2000-05-19	2013-10-23	埃米林药品公司	Glp-1用于制备治疗急性冠脉综合征的药物的用途
NZ519752A (en)	2000-10-20	2005-04-29	Amylin Pharmaceuticals Inc	Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
CA2430934C (fr)	2000-12-01	2011-06-21	Takeda Chemical Industries, Ltd.	Procede de production de preparations d'une substance bioactive a liberation prolongee a l'aide de gaz haute pression
DK1360202T3 (da) *	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
JP2002293799A (ja) *	2001-03-29	2002-10-09	Itoham Foods Inc	新規ペプチド及びそれを含有する消化管運動抑制剤
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (fr)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
DE60335608D1 (de) *	2002-02-27	2011-02-17	Pharmain Corp	Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
WO2004005342A1 (fr)	2002-07-04	2004-01-15	Zealand Pharma A/S	Glp-1 et methodes de traitement du diabete
BR0314996A (pt) *	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
JP2006514683A (ja) *	2002-10-07	2006-05-11	ザイモジェネティクス，インコーポレイティド	ヒトｚｖｅｎアンタゴニストの使用
EP1610811A4 (fr) *	2002-12-17	2008-03-26	Amylin Pharmaceuticals Inc	Prevention et traitement d'arythmies cardiaques
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1617888B1 (fr)	2003-04-23	2019-06-12	Valeritas, Inc.	Pompe hydraulique d'administration de medicaments sur de longues durees
US20060286129A1 (en) *	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
HRP20060362A2 (en) *	2004-04-23	2007-03-31	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
WO2005112977A2 (fr) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions de traitement avec un peptide de type glucagon, et procede de fabrication et d'utilisation de ces compositions
WO2006014425A1 (fr)	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Procedes et dispositifs pour l'administration du glp-1 et leurs utilisations
WO2006083761A2 (fr)	2005-02-03	2006-08-10	Alza Corporation	Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
DK1888103T3 (da) *	2005-04-11	2012-04-23	Amylin Pharmaceuticals Inc	Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
CN101258163B (zh)	2005-06-30	2013-08-21	益普生制药股份有限公司	Glp-1药物组合物
CA2622575A1 (fr) *	2005-09-13	2007-03-22	Zymogenetics, Inc.	Antagonistes prok2 et leurs procedes d'utilisation
US8039432B2 (en) *	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
US20070264130A1 (en) *	2006-01-27	2007-11-15	Phluid, Inc.	Infusion Pumps and Methods for Use
KR101361376B1 (ko)	2006-03-30	2014-02-10	발레리타스 인코포레이티드	복합-카트리지 유체 전달 장치
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (fr)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Système de libération osmotique avec ensemble de piston
WO2008133908A2 (fr)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Formulations en suspension de peptides insulinotropes et leurs utilisations
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
CA2726861C (fr)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
US20090287180A1 (en) *	2008-05-19	2009-11-19	Diperna Paul M	Disposable pump reservoir and related methods
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
CA2737461A1 (fr)	2008-09-19	2010-03-25	Tandem Diabetes Care, Inc.	Dispositif de mesure de la concentration d'un solute et procedes associes
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
PT2373681T (pt)	2008-12-10	2017-04-11	Glaxosmithkline Llc	Composições farmacêuticas de albiglutida
EP2216042A1 (fr)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	Compositions pharmaceutiques analogues au GLP-1
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
US8926561B2 (en)	2009-07-30	2015-01-06	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
WO2011064316A2 (fr)	2009-11-25	2011-06-03	Paolo Botti	Administration de peptides par voie muqueuse
WO2011123943A1 (fr)	2010-04-09	2011-10-13	Mount Sinai Hospital	Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
CN107129538B (zh)	2010-04-27	2021-07-16	西兰制药公司	Glp-1受体激动剂和胃泌素的肽缀合物及其用途
US8691763B2 (en)	2010-05-04	2014-04-08	Glaxosmithkline Llc	Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
JP2013530993A (ja)	2010-07-02	2013-08-01	アンジオケムインコーポレーテッド	治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9950038B2 (en)	2011-08-05	2018-04-24	The Trustees Of The Universiy Of Pennsylvania	Methods and compositions for inhibiting delayed graft function
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
JP6224586B2 (ja)	2012-07-10	2017-11-01	武田薬品工業株式会社	注射用製剤
IN2015DN00544A (fr)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2911686B1 (fr) *	2012-10-26	2021-07-28	University Health Network	Peptides de prévention d'une lésion tissulaire ischémique
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (fr)	2013-11-06	2015-05-14	Zealand Pharma A/S	Composés agonistes doubles de gip et glp-1 et procédés associés
WO2015086728A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
WO2015086733A1 (fr)	2013-12-13	2015-06-18	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
EP3080152A1 (fr)	2013-12-13	2016-10-19	Sanofi	Analogues peptidiques de l'exendine 4 non acylés
EP3080154B1 (fr)	2013-12-13	2018-02-07	Sanofi	Agonistes doubles du récepteur glp-1/gip
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
EP3229828B1 (fr)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
EP3296746A1 (fr) *	2016-09-20	2018-03-21	Université de Bourgogne	Procédé in vitro pour diagnostiquer une ischémie intestinale en premier développement
EP3551651B1 (fr)	2016-12-09	2024-03-06	Zealand Pharma A/S	Doubles agonistes glp-1/glp-2 acylés
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
DE102020103987A1 (de) *	2020-02-14	2021-08-19	Eberhard Karls Universität Tübingen, Medizinische Fakultät	Agens zur Behandlung und Prophylaxe einer postischämischen Gewebeschädigung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US61838A (en) *		1867-02-05		Eichaed ketcham
US4196196A (en)	1978-06-19	1980-04-01	Tiholiz Ivan C	Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4976959A (en)	1986-05-12	1990-12-11	Burroughs Wellcome Co.	T-PA and SOD in limiting tissue damage
US6204259B1 (en)	1993-01-14	2001-03-20	Monsanto Company	Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) †	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69523182T2 (de) *	1995-06-06	2002-02-07	Pfizer	Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
EP0958096A1 (fr)	1996-07-11	1999-11-24	Molins Plc	Procede et dispositif pour decouper/fermer des bandes
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
DE122007000044I2 (de) *	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
WO1998043658A1 (fr)	1997-03-31	1998-10-08	Eli Lilly And Company	Analogues de peptide 1 assimile au glucagon (glp-1)
US5955594A (en) *	1997-04-30	1999-09-21	Mishra; Lopa	Nucleic acids encoding proteins for early liver development
MY155270A (en) †	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US20020061838A1 (en)	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations

1999
- 1999-04-30 US US09/302,596 patent/US6284725B1/en not_active Expired - Lifetime
2000
- 2000-04-27 AT AT00926404T patent/ATE283701T1/de active
- 2000-04-27 PT PT00926404T patent/PT1173197E/pt unknown
- 2000-04-27 HK HK02108203.4A patent/HK1046640A1/zh unknown
- 2000-04-27 AU AU44935/00A patent/AU777019B2/en not_active Ceased
- 2000-04-27 JP JP2000615022A patent/JP2002543142A/ja active Pending
- 2000-04-27 DE DE60016393T patent/DE60016393T3/de not_active Expired - Lifetime
- 2000-04-27 WO PCT/US2000/011251 patent/WO2000066138A2/fr not_active Ceased
- 2000-04-27 CN CN00806951A patent/CN1349409A/zh active Pending
- 2000-04-27 NZ NZ514610A patent/NZ514610A/xx not_active IP Right Cessation
- 2000-04-27 MX MXPA01010859A patent/MXPA01010859A/es active IP Right Grant
- 2000-04-27 IL IL14583000A patent/IL145830A0/xx unknown
- 2000-04-27 EP EP00926404A patent/EP1173197B2/fr not_active Expired - Lifetime
- 2000-04-27 CA CA2372947A patent/CA2372947C/fr not_active Expired - Lifetime
- 2000-04-27 ES ES00926404T patent/ES2233366T5/es not_active Expired - Lifetime
- 2000-04-27 EP EP04027507A patent/EP1512410A1/fr not_active Withdrawn
2001
- 2001-05-09 US US09/851,738 patent/US6982248B2/en not_active Expired - Fee Related
- 2001-09-11 US US09/953,021 patent/US20020147131A1/en not_active Abandoned
- 2001-10-08 IL IL145830A patent/IL145830A/en not_active IP Right Cessation
- 2001-10-29 NO NO20015294A patent/NO325601B1/no not_active IP Right Cessation
2004
- 2004-12-21 AU AU2004240247A patent/AU2004240247B2/en not_active Ceased

Also Published As

Publication number	Publication date
CN1349409A (zh)	2002-05-15
CA2372947A1 (fr)	2000-11-09
US20020147131A1 (en)	2002-10-10
ES2233366T5 (es)	2012-01-27
JP2002543142A (ja)	2002-12-17
US6982248B2 (en)	2006-01-03
IL145830A (en)	2010-12-30
IL145830A0 (en)	2002-07-25
EP1173197B2 (fr)	2011-10-19
NZ514610A (en)	2004-01-30
US6284725B1 (en)	2001-09-04
DE60016393T2 (de)	2006-02-02
HK1046640A1 (zh)	2003-01-24
WO2000066138A3 (fr)	2001-07-05
EP1173197A2 (fr)	2002-01-23
DE60016393T3 (de)	2012-07-12
NO20015294L (no)	2001-12-28
PT1173197E (pt)	2005-04-29
AU4493500A (en)	2000-11-17
AU2004240247B2 (en)	2008-07-31
EP1173197B1 (fr)	2004-12-01
US20020055460A1 (en)	2002-05-09
ES2233366T3 (es)	2005-06-16
AU2004240247A1 (en)	2005-01-20
CA2372947C (fr)	2013-02-19
AU777019B2 (en)	2004-09-30
NO20015294D0 (no)	2001-10-29
EP1512410A1 (fr)	2005-03-09
ATE283701T1 (de)	2004-12-15
WO2000066138A2 (fr)	2000-11-09
MXPA01010859A (es)	2002-05-06
DE60016393D1 (de)	2005-01-05

Legal Events

Date	Code	Title	Description
2013-03-04	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ASTRAZENECA PHARMACEUTICALS LP, US
2016-11-28	MM1K	Lapsed by not paying the annual fees